Aprea Therapeutics partners with MD Anderson to explore APR-1051's efficacy against head and neck cancer in preclinical studies. Aprea Therapeutics, Inc. has announced a Material Transfer Agreement ...
APR-1051 targets WEE1 protein kinase, promoting cell cycle disruption and tumor cell death in HPV-positive cancers. ACESOT-1051 trial is evaluating APR-1051 in advanced solid tumors, with a focus on ...
Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patientThe unconfirmed ...
Investing.com -- Aprea Therapeutics Inc (NASDAQ:APRE) stock fell 19.7% Thursday after the clinical-stage biopharmaceutical ...
The chart below shows how APR-1051 potentiatiated the immune response to checkpoint inhibitors in an HPV+ HNSCC model. Clinical Update from Phase 1 ACESOT‑1051 Trial: In a 62-year-old male with ...
A newly approved National Cancer Institute-funded clinical trial aims to improve survival for head and neck cancer patients ...
BOSTON--(BUSINESS WIRE)--Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a predictive ...
WEE1 promotes immune resistance in NANOG-high tumors by activating the HSP90A/TCL1/AKT pathway, reducing the effectiveness of PD-1 blockade, and highlighting a promising target for cancer ...
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy Initial Phase 1 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results